Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil.In February, the FDA accepted and granted priority review to its biologics license application (BLA)Â seeking approval for valrox, its investigational a gene therapy for severe hemophilia A.